We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 12/1/2022

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

story of the week

Journal Scan / Research · September 27, 2022

Association of CRP Levels With Efficacy of Avelumab Plus Axitinib in Patients With Advanced RCC

ESMO Open

 

TAKE-HOME MESSAGE

abstract

This abstract is available on the publisher's site.

Access this abstract now   Full Text Available for ClinicalKey Subscribers

Additional Info

Disclosure statements are available on the authors' profiles:

ESMO Open
Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
ESMO Open 2022 Aug 26;7(5)100564, Y Tomita, J Larkin, B Venugopal, J Haanen, H Kanayama, M Eto, MO Grimm, Y Fujii, Y Umeyama, B Huang, M Mariani, A di Pietro, TK Choueiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading